[1] |
SEKERES M A. The epidemiology of myelodysplastic syndromes[J]. Hematol Oncol Clin North Am, 2010, 24(2):287-294. DOI: 10.1016/j.hoc.2010.02.011.
|
[2] |
PAPAEMMANUIL E, GERSTUNG M, MALCOVATI L,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes[J]. Blood, 2013, 122(22):3616-3627;quiz3699. DOI: 10.1182/blood-2013-08-518886.
|
[3] |
SCHANZ J, TÜCHLER H, SOLÉ F,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS)and oligoblastic acute myeloid leukemia after MDS derived from an international database merge[J]. J Clin Oncol, 2012, 30(8):820-829. DOI: 10.1200/JCO.2011.35.6394.
|
[4] |
GANGAT N, PATNAIK M M, TEFFERI A. Myelodysplastic syndromes:contemporary review and how we treat[J]. Am J Hematol, 2016, 91(1):76-89. DOI: 10.1002/ajh.24253.
|
[5] |
JILG S, REIDEL V, MÜLLER-THOMAS C,et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients[J]. Leukemia, 2016, 30(1):112-123. DOI: 10.1038/leu.2015.179.
|
[6] |
INVERNIZZI R, PECCI A, BELLOTTI L,et al. Expression of p53,bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes[J]. Leuk Lymphoma, 2001, 42(3):481-489. DOI: 10.3109/10428190109064605.
|
[7] |
CAMPOS L, ROUAULT J P, SABIDO O,et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy[J]. Blood,1993,81(11):3091-3096.
|
[8] |
BANKER D E, RADICH J, BECKER A,et al. The t(8;21)translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults[J]. Clin Cancer Res,1998,4(12):3051-3062.
|
[9] |
POLLYEA D A, BIXBY D, PERL A,et al. NCCN guidelines insights:acute myeloid leukemia,version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(1):16-27. DOI: 10.6004/jnccn.2021.0002.
|
[10] |
|
[11] |
CAZZOLA M. Introduction to a review series:the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues[J]. Blood, 2016, 127(20):2361-2364. DOI: 10.1182/blood-2016-03-657379.
|
[12] |
|
[13] |
DINARDO C D, RAUSCH C R, BENTON C,et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J]. Am J Hematol, 2018, 93(3):401-407. DOI: 10.1002/ajh.25000.
|
[14] |
CHESON B D, GREENBERG P L, BENNETT J M,et al. Clinical application and proposal for modification of the International Working Group(IWG)response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425. DOI: 10.1182/blood-2005-10-4149.
|
[15] |
CHESON B D, BENNETT J M, KANTARJIAN H,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes[J]. Blood,2000,96(12):3671-3674.
|
[16] |
GREENBERG P L, TUECHLER H, SCHANZ J,et al. Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465. DOI: 10.1182/blood-2012-03-420489.
|
[17] |
DE WITTE T, BOWEN D, ROBIN M,et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML:recommendations from an international expert panel[J]. Blood, 2017, 129(13):1753-1762. DOI: 10.1182/blood-2016-06-724500.
|
[18] |
FENAUX P, MUFTI G J, HELLSTROM-LINDBERG E,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised,open-label,phaseⅢ study[J]. Lancet Oncol, 2009, 10(3):223-232. DOI: 10.1016/S1470-2045(09)70003-8.
|
[19] |
PARKER J E, MUFTI G J, RASOOL F,et al. The role of apoptosis,proliferation,and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS[J]. Blood,2000,96(12):3932-3938.
|
[20] |
SHIMONY S, STAHL M, STONE R M. Acute myeloid leukemia:2023 update on diagnosis,risk-stratification,and management[J]. Am J Hematol, 2023, 98(3):502-526. DOI: 10.1002/ajh.26822.
|
[21] |
GIUDICE V, SERIO B, FERRARA I,et al. Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes:a single-center real-life experience[J]. Front Pharmacol, 2022, 13:1052060. DOI: 10.3389/fphar.2022.1052060.
|
[22] |
BALL B J, FAMULARE C A, STEIN E M,et al. Venetoclax and hypomethylating agents (HMAs)induce high response rates in MDS,including patients after HMA therapy failure[J]. Blood Adv, 2020, 4(13):2866-2870. DOI: 10.1182/bloodadvances.2020001482.
|
[23] |
PRÉBET T, GORE S D, ESTERNI B,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure[J]. J Clin Oncol, 2011, 29(24):3322-3327. DOI: 10.1200/jco.2011.35.8135.
|
[24] |
JABBOUR E J, GARCIA-MANERO G, STRATI P,et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure:a report on behalf of the MDS Clinical Research Consortium[J]. Cancer, 2015, 121(6):876-882. DOI: 10.1002/cncr.29145.
|